A Phase I, Randomized, Double-Blind (With-in Panel), Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Healthy Elderly Volunteers After Oral Multiple Ascending Doses of AZD0328
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2010
At a glance
- Drugs AZD 0328 (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions
- 09 Dec 2010 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 19 Jun 2008 New trial record.